Blandino Ortiz Aaron, Belliato Mirko, Broman Lars Mikael, Lheureux Olivier, Malfertheiner Maximilian Valentin, Xini Angela, Pappalardo Federico, Taccone Fabio Silvio
Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, B-1070 Brussels, Belgium.
UOS Advanced Respiratory Intensive Care Unit, UOC Anestesia e Rianimazione 1, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Membranes (Basel). 2021 Jan 22;11(2):81. doi: 10.3390/membranes11020081.
Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat cardiopulmonary failure in critically ill patients. Peripheral cannulation may be complicated by a persistent low cardiac output in case of veno-venous cannulation (VV-ECMO) or by differential hypoxia (e.g., lower PaO in the upper than in the lower body) in case of veno-arterial cannulation (VA-ECMO) and severe impairment of pulmonary function associated with cardiac recovery. The treatment of such complications remains challenging. We report the early effects of the use of veno-arterial-venous (V-AV) ECMO in this setting.
Retrospective analysis including patients from five different European ECMO centers (January 2013 to December 2016) who required V-AV ECMO. We collected demographic data as well as comorbidities and ECMO characteristics, hemodynamics, and arterial blood gas values before and immediately after (i.e., within 2 h) V-AV implementation.
A total of 32 patients (age 53 (interquartiles, IQRs: 31-59) years) were identified: 16 were initially supported with VA-ECMO and 16 with VV-ECMO. The median time to V-AV conversion was 2 (1-5) days. After V-AV implantation, heart rate and norepinephrine dose significantly decreased, while PaO and SaO significantly increased compared to baseline values. Lactate levels significantly decreased from 3.9 (2.3-7.1) to 2.8 (1.4-4.4) mmol/L ( = 0.048). A significant increase in the overall ECMO blood flow (from 4.5 (3.8-5.0) to 4.9 (4.3-5.9) L/min; < 0.01) was observed, with 3.0 (2.5-3.2) L/min for the arterial and 2.8 (2.1-3.6) L/min for the venous return flows.
In ECMO patients with differential hypoxia or persistently low cardiac output syndrome, V-AV conversion was associated with improvement in some hemodynamic and respiratory parameters. A significant increase in the overall ECMO blood flow was also observed, with similar flow distributed into the arterial and venous return cannulas.
体外膜肺氧合(ECMO)越来越多地用于治疗危重症患者的心肺衰竭。在静脉-静脉插管(VV-ECMO)时,外周插管可能会并发持续性低心输出量;在静脉-动脉插管(VA-ECMO)时,可能会出现差异性低氧血症(如下半身的动脉血氧分压(PaO)高于上半身),且与心脏恢复相关的肺功能严重受损。此类并发症的治疗仍然具有挑战性。我们报告了在这种情况下使用静脉-动脉-静脉(V-AV)ECMO的早期效果。
对来自五个不同欧洲ECMO中心(2013年1月至2016年12月)需要V-AV ECMO的患者进行回顾性分析。我们收集了人口统计学数据以及合并症、ECMO特征、血流动力学指标以及在实施V-AV之前和之后(即2小时内)的动脉血气值。
共确定了32例患者(年龄53(四分位数间距,IQR:31-59)岁):16例最初接受VA-ECMO支持,16例接受VV-ECMO支持。转为V-AV的中位时间为2(1-5)天。植入V-AV后,心率和去甲肾上腺素剂量显著降低,而与基线值相比,PaO和SaO显著升高。乳酸水平从3.9(2.3-7.1)mmol/L显著降至2.8(1.4-4.4)mmol/L(P = 0.048)。观察到ECMO总血流量显著增加(从4.5(3.8-5.0)L/分钟增至4.9(4.3-5.9)L/分钟;P < 0.01),动脉血流量为3.0(2.5-3.2)L/分钟,静脉回流血流量为2.8(2.1-3.6)L/分钟。
在患有差异性低氧血症或持续性低心输出量综合征的ECMO患者中,转为V-AV与一些血流动力学和呼吸参数的改善相关。还观察到ECMO总血流量显著增加,且动脉和静脉回流插管中的血流量相似。